nach oben

Hepatology International

Erschienen in:

01.12.2009 | SUPPLEMENT ARTICLE

On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48

verfasst von: Ting-Tsung Chang

Erschienen in: Hepatology International | Sonderheft 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The suppression of hepatitis B viral (HBV) load correlates with favorable histologic, biochemical, and serologic responses in clinical trials of patients with chronic hepatitis B (CHB). The ability to identify patients who will not experience durable viral suppression in response to a specific antiviral regimen affords the opportunity for early treatment modification to optimize outcomes and avoid the development of antiviral resistance. Substantial evidence demonstrates that on-treatment serum HBV DNA levels are predictive of virologic response and risk of resistance. Regional clinical practice guidelines for the management of CHB universally recommend monitoring serum HBV DNA levels at treatment week 24. However, the value of this time point as a predictor of long-term success may not be applicable to all types of antiviral therapy. Indeed, each oral nucleos(t)ide analog (NA) antiviral therapy has a unique profile of potency, genetic barriers to resistance, and viral kinetics that may affect the optimal time point for on-treatment monitoring. This review discusses available data for appropriate predictors for long-term response and antiviral resistance for patients receiving specific oral NA antiviral therapy. Guidelines for on-treatment monitoring are also discussed.

Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al., for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263–283

Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–539PubMedCrossRef

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–242PubMedCrossRef

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al., for the Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–1531

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al., for the Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576–2588

Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al., for the GLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486–495

Zeuzem S, Gane E, Liaw YK, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11–20PubMedCrossRef

Bristol Myers-Squibb. Entecavir AVDAC briefing document; 2005. Available from: http://www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4094B1_01_BristolMyersSquibb-entecavir.pdf. Accessed 1 June 2009

Lee HW, Kim HJ, Kim MH, Kim KA, Lee JS, Sul HR, et al. Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks. Hepatology 2008;48(Suppl):741A. Abstract No.: 969

10.

Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113–120PubMedCrossRef

11.

Zöllner B, Schäfer P, Feucht HH, Schröter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659–663PubMedCrossRef

12.

Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757–1762PubMedCrossRef

13.

Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785–791PubMedCrossRef

14.

Hadziyannis A, Mitsoula PV, Hadziyannis SJ. Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg negative chronic hepatitis B. Hepatology 2007;46(Suppl):667A

15.

Pritchett S, Wong DK, Yim C, Mazzulli T, Heathcote EJ. Factors affecting response to adefovir treatment in patients with chronic hepatitis B and lamivudine resistance. Hepatology 2007;46(Suppl):675A

16.

Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Hepatology 2007;46:861A. Abstract No.: LB7CrossRef

17.

Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890–897PubMedCrossRef

18.

Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008;14:6902–6910PubMedCrossRef

19.

Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149–155PubMedCrossRef

20.

Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009;14:13–22PubMed

21.

Ghany MG, Strader DB, Thomas DL, Seeff LB, for the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374

22.

Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements of the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615–633

23.

Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634–651PubMedCrossRef

24.

van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HLA, Schalm SW, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepatol 2006;13:96–103CrossRef

25.

Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186–194PubMedCrossRef

26.

Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12:345–353PubMed

27.

Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007;22:1078–1085PubMedCrossRef

28.

Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW et al., for the Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528–536

29.

Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695–1703PubMedCrossRef

30.

Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. J Hepatol 2009;50(Suppl):S10. Abstract No.: 20CrossRef

31.

Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503–1514PubMedCrossRef

32.

Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656–1665PubMedCrossRef

33.

Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Long-term resistance profile of entecavir in nucleoside-naïve patients with chronic hepatitis B from worldwide and Japanese development programs. Proceedings of the Conference of Hepatitis C and B Virus: Resistance to Antiviral Therapies; 2006 Feb 14–16; Paris, France. Available from: http://www.easl.ch/hepatitis-conference/program/session1.asp. Accessed 2 June 2009

34.

Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437–1444PubMedCrossRef

35.

Han SH, Chang TT, Chao YC, Yoon SK, Gish RG, Cheinquer H, et al. Five years of continuous entecavir for nucleoside-naïve HBeAg(+) chronic hepatitis B: results from study ETV-901. Abstract No.: OP-48. Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease; 2009 Mar 20–24; Washington, DC. Available from: http://www.isvhld2009.org/pdfs/sunday_March22_Abstracts.pdf. Accessed 2 June 2009

36.

Ma H, Ren JB, Li HY, Wang Y, Wang RL, Liang L, et al. Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007;21:102–104PubMed

37.

Hsu CW, Chen YC, Liaw YF, Gane E, Manns M, Zeuzem S, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. J Hepatol 2009;50:S331. Abstract No.: 911CrossRef

38.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–2455PubMedCrossRef

39.

Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al., for the 018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745–754

40.

Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72–79PubMedCrossRef

41.

Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005;42(Suppl):17. Abstract No.: 36

42.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al., for the Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743–1751

43.

Heathcote J, George S, Gordon JP, Bronowicki J, Sperl R, Williams P, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J Hepatol 2008;48:S32. Abstract No.: 72CrossRef

44.

Marcellin P, Jacobson I, Habersetzer F, Senturk H, Andreone P, Moyes C, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch study (study 102). J Hepatol 2008;48:S26. Abstract No.: 57CrossRef

45.

Snow-Lampart S, Chappell B, Curtis M, Zhu Y, Heathcote J, Marcellin P, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd. Abstract No.: OP-82. Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease; 2009 Mar 20–24; Washington, DC. Available from: http://www.isvhld2009.org/pdfs/sunday_March22_Abstracts.pdf. Accessed 2 June 2009

Titel: On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48
verfasst von: Ting-Tsung Chang
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Hepatology International / Ausgabe Sonderheft 1/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-009-9143-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2009

The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B

CME post test

Chronic hepatitis B in Asian women of childbearing age

Introduction

CME information